Business Description
Neuren Pharmaceuticals Ltd
ISIN : NZNEUE0001S8
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.83 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 38.87 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Book Growth Rate | 97.3 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 47.53 | |||||
9-Day RSI | 42.26 | |||||
14-Day RSI | 42.26 | |||||
6-1 Month Momentum % | 107.43 | |||||
12-1 Month Momentum % | 49.44 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.78 | |||||
Quick Ratio | 5.78 | |||||
Cash Ratio | 5.34 | |||||
Days Sales Outstanding | 11.08 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -3.3 | |||||
Shareholder Yield % | -0.15 |
Profitability Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | 85.9 | |||||
Net Margin % | 67.73 | |||||
FCF Margin % | 79.72 | |||||
ROE % | 139.29 | |||||
ROA % | 121.22 | |||||
ROIC % | 897.02 | |||||
ROC (Joel Greenblatt) % | 11699.94 | |||||
ROCE % | 176.65 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 16.03 | |||||
Forward PE Ratio | 34.48 | |||||
PE Ratio without NRI | 16.03 | |||||
Shiller PE Ratio | 384.11 | |||||
Price-to-Owner-Earnings | 15.53 | |||||
PS Ratio | 11 | |||||
PB Ratio | 12.16 | |||||
Price-to-Tangible-Book | 12.18 | |||||
Price-to-Free-Cash-Flow | 13.84 | |||||
Price-to-Operating-Cash-Flow | 13.83 | |||||
EV-to-EBIT | 11.02 | |||||
EV-to-Forward-EBIT | 26.41 | |||||
EV-to-EBITDA | 11.02 | |||||
EV-to-Forward-EBITDA | 26.41 | |||||
EV-to-Revenue | 9.46 | |||||
EV-to-Forward-Revenue | 19.02 | |||||
EV-to-FCF | 11.87 | |||||
Price-to-Projected-FCF | 6.62 | |||||
Price-to-Graham-Number | 2.94 | |||||
Price-to-Net-Current-Asset-Value | 12.18 | |||||
Price-to-Net-Cash | 13.46 | |||||
Earnings Yield (Greenblatt) % | 9.07 | |||||
FCF Yield % | 7.63 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Neuren Pharmaceuticals Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil A$) | 231.925 | ||
EPS (TTM) (A$) | 1.201 | ||
Beta | 2.45 | ||
Volatility % | 81.73 | ||
14-Day RSI | 42.26 | ||
14-Day ATR (A$) | 0.699077 | ||
20-Day SMA (A$) | 20.0845 | ||
12-1 Month Momentum % | 49.44 | ||
52-Week Range (A$) | 10.02 - 25.95 | ||
Shares Outstanding (Mil) | 129.95 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Neuren Pharmaceuticals Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Neuren Pharmaceuticals Ltd Stock Events
Event | Date | Price(A$) | ||
---|---|---|---|---|
No Event Data |
Neuren Pharmaceuticals Ltd Frequently Asked Questions
What is Neuren Pharmaceuticals Ltd(ASX:NEU)'s stock price today?
When is next earnings date of Neuren Pharmaceuticals Ltd(ASX:NEU)?
Does Neuren Pharmaceuticals Ltd(ASX:NEU) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |